Last reviewed · How we verify
YARTEMLEA (NARSOPLIMAB-WUUG)
YARTEMLEA (generic name: NARSOPLIMAB-WUUG) is a drug developed by OMEROS CORP. It is currently FDA-approved.
At a glance
| Generic name | NARSOPLIMAB-WUUG |
|---|---|
| Sponsor | OMEROS CORP |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
- Hemorrhage
- Diarrhea
- Viral infections
- Neutropenia
- Pyrexia
- Vomiting
- Fatigue
- Hypokalemia
- Nausea
- Sepsis
- Pneumonia
- Hypotension
Serious adverse events
- Acute kidney injury
- Confusional state
- Acute respiratory failure
- Neutropenic sepsis
- Septic shock
- Pulmonary edema
- Acute myocardial infarction
- Pulmonary alveolar hemorrhage
- Escherichia sepsis
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- YARTEMLEA CI brief — competitive landscape report
- YARTEMLEA updates RSS · CI watch RSS
- OMEROS CORP portfolio CI
Frequently asked questions about YARTEMLEA
What is YARTEMLEA?
YARTEMLEA (NARSOPLIMAB-WUUG) is a pharmaceutical drug developed by OMEROS CORP.
Who makes YARTEMLEA?
YARTEMLEA is developed and marketed by OMEROS CORP (see full OMEROS CORP pipeline at /company/omeros-corp).
What is the generic name of YARTEMLEA?
NARSOPLIMAB-WUUG is the generic (nonproprietary) name of YARTEMLEA.
What development phase is YARTEMLEA in?
YARTEMLEA is FDA-approved (marketed).
What are the side effects of YARTEMLEA?
Common side effects of YARTEMLEA include Hemorrhage, Diarrhea, Viral infections, Neutropenia, Pyrexia, Vomiting. Serious adverse events: Acute kidney injury, Confusional state, Acute respiratory failure, Neutropenic sepsis.
Related
- Manufacturer: OMEROS CORP — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing